Everything below concerns visceral adiposity. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-12. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Valorous Unit Award, Streamer embroidered AFGHANISTAN 2011–2012 Meritorious Unit Commendation (Army), Streamer embroidered WAR ON TERRORISM 2011–2012 Company A, 3d Special Forces Battalion entitled to: Presidential Unit Citation (Army), Streamer embroidered AFGHANISTAN JUL-DEC 2016 Valorous Unit Award, Streamer embroidered AFGHANISTAN JUN-AUG 2010 Company B, 3d Special Forces Battalion entitled to: Meritorious Unit Commendation (Army), Streamer embroidered AFGHANISTAN AUG 2010-APR 2011 4th Special Forces Battalion entitled to:
== Geography == It consisted of two detached parts of the Mecklenburg region: the larger Lordship of Stargard with the residence of Neustrelitz to the southeast of the Grand Duchy of Mecklenburg-Schwerin and the Principality of Ratzeburg on the west. The first was bounded by the Prussian provinces of Pomerania and Brandenburg, the second bordered on the Duchy of Lauenburg (incorporated into the Province of Schleswig-Holstein in 1876) and the territory of the Free City of Lübeck. Major towns beside Neustrelitz included Neubrandenburg, Friedland, Woldegk, Stargard, Fürstenberg, and Wesenberg. The grand duchy also comprised the former commandries of the Knights Hospitaller in Mirow and Nemerow.
234U occurs in natural uranium as an indirect decay product of uranium-238, but makes up only 55 parts per million of the uranium because its half-life of 245,500 years is only about 1/18,000 that of 238U. The path of production of 234U is this: 238U alpha decays to thorium-234. Next, with a short half-life, 234Th beta decays to protactinium-234. Finally, 234Pa beta decays to 234U. 234U alpha decays to thorium-230, except for a small percentage of nuclei that undergo spontaneous fission. Extraction of small amounts of 234U from natural uranium could be done using isotope separation, similar to normal uranium-enrichment. However, there is no real demand in chemistry, physics, or engineering for isolating 234U. Very small pure samples of 234U can be extracted via the chemical ion-exchange process, from samples of plutonium-238 that have aged somewhat to allow some alpha decay to 234U. Enriched uranium contains more 234U than natural uranium as a byproduct of the uranium enrichment process aimed at obtaining uranium-235, which concentrates lighter isotopes even more strongly than it does 235U. The increased percentage of 234U in enriched natural uranium is acceptable in current nuclear reactors, but (re-enriched) reprocessed uranium might contain even higher fractions of 234U, which is undesirable. This is because 234U is not fissile, though it is fertile. It tends to absorb slow neutrons in a nuclear reactor, becoming fissile 235U.
Sources: en.wikipedia.org
Silicosis is the most common occupational lung disease worldwide. Because of work-exposure to silica dust, silicosis is an occupational hazard to construction, railroad, demolition, mining, sandblasting, quarry, tunnelling, ceramics and foundry workers, as well as grinders, stone countertop fabricators, refractory brick workers, tombstone workers, workers in the oil and gas industry, pottery workers, fiberglass manufacturing, glass manufacturing, flintknappers and others. Brief or casual exposure to low levels of crystalline silica dust do not produce clinically significant lung disease. In the United States, it is estimated that between one and two million workers have had occupational exposure to crystalline silica dust and 59,000 of these workers will develop silicosis sometime in the course of their lives. In the US between 1995 and 2004, there was an annual recorded average of roughly 30 silicosis-related deaths. In the UK, the latest data from The Health and Safety Executive show that there are typically between 10 and 20 annual silicosis deaths in recent years, with an average of 12 per year over the last 10 years. There has been a recent rise of cases in Australia, China and the United States associated with the manufacture and installation of engineered stone surfaces in kitchens and bathrooms. Engineered stone has become increasingly common, and it contains a very high proportion of silica, more than natural stone.
=== Lymph production === Because the pores in the hepatic sinusoids are very permeable and allow ready passage of both fluid and proteins into the perisinusoidal space, the lymph draining from the liver usually has a protein concentration of about 6 g/dl, which is only slightly less than the protein concentration of plasma. Also, the high permeability of the liver sinusoid epithelium allows large quantities of lymph to form. Therefore, about half of all the lymph formed in the body under resting conditions arises in the liver.
nucleophile Any atom or molecule which can donate an electron pair to another atom or molecule. All molecules or ions with a free pair of electrons or at least one pi bond can act as nucleophiles, by which they are attracted to electron-deficient regions of other species; a chemical reaction involving a nucleophile donating an electron pair to an electrophile may be referred to as nucleophilic attack. Because they donate electrons, nucleophiles are Lewis bases by definition.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.